fbpx Skip to main content

MONDAY, Dec. 28, 2020 (HealthDay News) — Risk factors for mortality in hospitalized patients with COVID-19 include male sex, hypertension and diabetes with chronic complications, and obesity, according to a study published online Dec. 18 in Clinical Infectious Diseases.

Katherine E. Goodman, J.D., Ph.D., from The University of Maryland School of Medicine in Baltimore, and colleagues performed a retrospective cohort study of COVID-19 inpatients to examine the correlation between patient characteristics and mortality across age groups. Data were included for 66,646 admissions with a COVID-19 diagnosis across 613 U.S. hospitals.

The researchers found that 18.6 percent of the patients died in hospital. Male sex was independently associated with increased mortality risk in a multivariable analysis (adjusted relative risk [aRR], 1.30; 95 percent confidence interval [CI], 1.26 to 1.34). At no age was diabetes without chronic complications a risk factor (aRR, 1.01; 95 percent CI, 0.96 to 1.06); for those aged 20 to 39 years only, hypertension without chronic complications was a risk factor (aRR, 1.68; 95 percent CI, 1.17 to 2.40). In most age groups, diabetes with chronic complications, hypertension with chronic complications, and obesity were risk factors, with the highest relative risks among those aged 20 to 39 years (aRRs [95 percent CIs], 1.79 [1.23 to 2.61], 2.33 [1.50 to 3.60], and 1.92 [1.43 to 2.57], respectively; P values ≤ 0.002).

“Predicting which hospitalized COVID-19 patients have the highest risk of dying has taken on urgent importance as cases and hospitalizations in the United States continue to surge to record high numbers during the month of December,” a coauthor said in a statement.

One author disclosed financial ties to UpToDate.

You May Also Like::  Patients Happier With Doctors of Same Race

Abstract/Full Text (subscription or payment may be required)

“Keeping up with the indications and adverse reactions to immune checkpoint inhibitors can be a full-time job. Cutaneous side effects occur in up to 45% of patients treated with ipilimumab and 34% of patients treated with nivolumab and pembrolizumab.” https://bit.ly/3FGtxtd

.@spfnomt: This month’s #DermWorld article “Estate planning 101” is especially important for young physicians to read. The long, all-consuming years between adolescence and physicianhood can become a blur...https://bit.ly/3FxOtCv

That’s a wrap #AAD2023! 5 days of soaking up knowledge from dermatologists on topics such as hidradenitis, melasma, & dietary triggers of common dermatoses.

I LOVED the #womenshealth focused sessions on vulvar dermatoses and pregnancy medication safety.


New approach uses microbiome to treat skin disease by repairing the injured microbiome that allowed inflammation to flare up in the first place, rather than reducing the inflammation after the fact. https://bit.ly/3Jt6H9v

Load More